Introduction Endovascular therapy in acute ischemic stroke is safe and efficient. However, patients receiving oral anticoagulation were excluded in the larger trials.
Objective To analyze the safety of endovascular therapy in patients with acute ischemic stroke and elevated international normalized ratio (INR) values.
Methods Retrospective database review of a tertiary care university hospital for patients with anterior circulation stroke treated with endovascular therapy. Patients with anticoagulation other than vitamin K antagonists were excluded. The primary safety endpoint was defined as symptomatic intracranial hemorrhage (sICH; ECASS II definition). The efficacy endpoint was the modified Rankin scale (mRS) score after 3 months, dichotomized into favorable outcome (mRS 0–2) and unfavorable outcome (mRS 3–6).
Results 435 patients were included. 90% were treated with stent retriever. 27 (6.2%) patients with an INR of 1.2–1.7 and 21 (4.8%) with an INR >1.7. 33 (7.6%) had sICH and 149 patients (34.3%) had a favorable outcome. Patients with an elevated INR did not have an increased risk for sICH or unfavorable outcome in multivariable analysis. The additional use of IV thrombolysis in patients with an INR of 1.2–1.7 did not increase the risk of sICH or unfavorable outcome. These results were replicated in a sensitivity analysis introducing an error of the INR of ±5%. They were also confirmed using other sICH definitions (Safe Implementation of Thrombolysis in Stroke (SITS), National Institute of neurological Disorders and Stroke (NINDS), Heidelberg bleeding classification).
Conclusions Endovascular therapy in patients with an elevated INR is safe and efficient. Patients with an INR of 1.2–1.7 may be treated with combined IV thrombolysis and endovascular therapy.
Statistics from Altmetric.com
Contributors SM planned and conducted the study. He analyzed and interpreted the data, wrote the initial draft of the manuscript, and revised the manuscript for important intellectual content. He is guarantor. AT conducted the study, analyzed the data, and revised the manuscript for important intellectual content. MAM acquired data for the study and revised the manuscript for important intellectual content. MB revised the manuscript for important intellectual content. PAR acquired data for the study, interpreted the results, revised the manuscript for important intellectual content, and supervised the study. He is guarantor.
Competing interests None declared.
Ethics approval Ethics committee of the University of Heidelberg.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.